v3.25.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Other Comprehensive Loss [Member]
Balance at the beginning at Jun. 30, 2023 $ 202 $ 0 $ 168,921 $ (167,889) $ (830)
Balance at the beginning (In shares) at Jun. 30, 2023   1,671,485      
Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $2,964 27,919 $ 0 27,919    
Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $2,964, Shares   875,949      
Anti-dilution adjustment to warrants     619 (619)  
Share-based compensation 91   91    
Foreign currency translation gain (loss) 50       50
Net loss (5,954)     (5,954)  
Balance at end at Sep. 30, 2023 22,308 $ 0 197,550 (174,462) (780)
Balance at end (In shares) at Sep. 30, 2023   2,547,434      
Balance at the beginning at Jun. 30, 2023 202 $ 0 168,921 (167,889) (830)
Balance at the beginning (In shares) at Jun. 30, 2023   1,671,485      
Foreign currency translation gain (loss) (5)        
Net loss (17,031)        
Balance at end at Mar. 31, 2024 11,500 $ 0 197,874 (185,539) (835)
Balance at end (In shares) at Mar. 31, 2024   2,724,794      
Balance at the beginning at Sep. 30, 2023 22,308 $ 0 197,550 (174,462) (780)
Balance at the beginning (In shares) at Sep. 30, 2023   2,547,434      
Exercise of pre-funded warrants, Shares   25,000      
Exercise of Series 2 warrants 39   39    
Exercise of Series 2 warrants (In shares)   20,000      
Share-based compensation 93   93    
Foreign currency translation gain (loss) (172)       (172)
Net loss (6,798)     (6,798)  
Balance at end at Dec. 31, 2023 15,470 $ 0 197,682 (181,260) (952)
Balance at end (In shares) at Dec. 31, 2023   2,592,434      
Exercise of pre-funded warrants, Shares   132,360      
Share-based compensation 192   192    
Foreign currency translation gain (loss) 117       117
Net loss (4,279)     (4,279)  
Balance at end at Mar. 31, 2024 11,500 $ 0 197,874 (185,539) (835)
Balance at end (In shares) at Mar. 31, 2024   2,724,794      
Balance at the beginning at Jun. 30, 2024 47,248 $ 1 238,398 (190,259) (892)
Balance at the beginning (In shares) at Jun. 30, 2024   10,086,119      
Exercise of pre-funded warrants, Shares   1,768,454      
Exercise of Series 2 warrants 1,655   1,655    
Exercise of Series 2 warrants (In shares)   857,845      
Exercise of common warrants 20,002   20,002    
Exercise of common warrants (Shares)   5,181,347      
Share-based compensation 435   435    
Foreign currency translation gain (loss) (101)       (101)
Net loss (5,059)     (5,059)  
Balance at end at Sep. 30, 2024 64,180 $ 1 260,490 (195,318) (993)
Balance at end (In shares) at Sep. 30, 2024   17,893,765      
Balance at the beginning at Jun. 30, 2024 47,248 $ 1 238,398 (190,259) (892)
Balance at the beginning (In shares) at Jun. 30, 2024   10,086,119      
Foreign currency translation gain (loss) 176        
Net loss (21,770)        
Balance at end at Mar. 31, 2025 97,570 $ 2 310,313 (212,029) (716)
Balance at end (In shares) at Mar. 31, 2025   25,546,288      
Balance at the beginning at Sep. 30, 2024 64,180 $ 1 260,490 (195,318) (993)
Balance at the beginning (In shares) at Sep. 30, 2024   17,893,765      
Exercise of pre-funded warrants, Shares   606,129      
Exercise of Series 2 warrants 1,240   1,240    
Exercise of Series 2 warrants (In shares)   642,160      
Exercise of common warrants 16,630   16,630    
Exercise of common warrants (Shares)   4,309,421      
Share-based compensation 943   943    
Foreign currency translation gain (loss) 305       305
Net loss (7,357)     (7,357)  
Balance at end at Dec. 31, 2024 75,941 $ 1 279,303 (202,675) (688)
Balance at end (In shares) at Dec. 31, 2024   23,451,475      
Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $2,964 28,213 $ 1 28,212    
Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $2,964, Shares   2,043,000      
Exercise of common warrants 201   201    
Exercise of common warrants (Shares)   51,813      
Share-based compensation 2,597   2,597    
Foreign currency translation gain (loss) (28)       (28)
Net loss (9,354)     (9,354)  
Balance at end at Mar. 31, 2025 $ 97,570 $ 2 $ 310,313 $ (212,029) $ (716)
Balance at end (In shares) at Mar. 31, 2025   25,546,288